Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Treating inflammatory bowel disease (IBD) with antidepressants might be of utility to improve patient's condition. The aim of this study was to assess the efficacy of Duloxetine on depression, anxiety, severity of symptoms, and quality of life (QOL) in IBD patients. MATERIALS AND METHODS: In a randomized, double-blind, controlled clinical trial on 2013-2014, in Alzahra Hospital (Isfahan, Iran), 44 IBD patients were chosen to receive either duloxetine (60 mg/day) or placebo. They were treated in a 12 weeks program, and all of the participants also received mesalazine, 2-4 g daily. We assessed anxiety and depression with Hospital Anxiety and Depression Scale, the severity of symptoms with Lichtiger Colitis Activity Index and QOL with World Health Organization Quality of Life Instruments, before and just after the treatment. The data were analyzed using Paired sample t-test and ANCOVA. RESULTS: In 35 subjects who completed the study, the mean (standard error [SE]) scores of depression and anxiety were reduced in duloxetine more than placebo group, significantly (P = 0.041 and P = 0.049, respectively). The mean (SE) scores of severity of symptom were also reduced in duloxetine more than the placebo group, significantly (P = 0.02). The mean (SE) scores of physical, psychological, and social dimensions of QOL were increased after treatment with duloxetine more than placebo group, significantly (P = 0.001, P = 0.038, and P = 0.015, respectively). The environmental QOL was not increased significantly (P = 0.260). CONCLUSION: Duloxetine is probably effective and safe for reducing depression, anxiety and severity of physical symptoms. It also could increase physical, psychological, and social QOL in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skevington, S. M., Lotfy, M., & O'Connell, K. A. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018486.91360.00 · Cited by 4,686 · cited 1×
“It is consisted of four domains including physical, psychological, social, and environment.[28,29] The translation and back-translation method were used to prepare the Persian translation of LCAI and WHOQOL-BREF questioners.”
Structured Clinical Interview for DSM-III-R Personality Disorders
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (2012) · PsycTESTS Dataset · doi:10.1037/t07827-000 · Cited by 1,403
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-14 · Cited by 640
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Mittermaier, C., Dejaco, C., Waldhoer, T., Oefferlbauer-Ernst, A., Miehsler, W., Beier, M., Tillinger, W., Gangl, A., & Moser, G. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000106907.24881.f2 · Cited by 532
Graff, L. A., Walker, J. R., Lix, L., Clara, I., Rawsthorne, P., Rogala, L., Miller, N., Jakul, L., McPhail, C., Ediger, J., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.027 · Cited by 292 · cited 1×
“Interestingly, Psychological status has been found to impact the course of the disease.[3,4] There is an important pathophysiological relations and common pathways between some psychiatric disorders such as anxiety or depression and IBD, which is related to impaired function of immunoregulatory circuits.”
Ghia, J.-E., Blennerhassett, P., & Collins, S. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32849 · Cited by 233 · cited 1×
“[3,4] There is an important pathophysiological relations and common pathways between some psychiatric disorders such as anxiety or depression and IBD, which is related to impaired function of immunoregulatory circuits.[5,6,7,8] Clinical studies shows that many of the patients experience depression and anxiety that is…”
Cuijpers, P., van Straten, A., van Oppen, P., & Andersson, G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1102 · Cited by 219 · cited 1×
“The most used treatments are psychological interventions such as cognitive behavior therapies and pharmacological treatments especially the selective serotonin reuptake inhibitors (SSRIs) and the serotonin-norepinephrine reuptake inhibitors (SNRIs).[17,18,19] On the other hand, it has been shown that antidepressants h…”
Mardini, H. E., Kip, K. E., & Wilson, J. W. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000020509.23162.cc · Cited by 211 · cited 5×
“Several studies had suggested that higher depression and anxiety scores are associated with the detrimental impact on disease activity, treatment response, relapses, and overall QOL.[10,13,31] Consistently, in this study, treating of patients with duloxetine, not only reduced depression and anxiety but also the severi…”
InfluentialPsychological interventions for treatment of inflammatory bowel disease
Timmer, A., Preiss, J. C., Motschall, E., Rücker, G., Jantschek, G., & Moser, G. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006913.pub2 · Cited by 187 · cited 1×
“[12] Clinical studies for psychological interventions have recently been conducted, but antidepressants have not been studied in the IBD patients widely.[21] Some studies have suggested that treating patients with antidepressants might be of utility to control disease severity, increase QOL and lengthen remission; but…”
Research works printed but not linked: 25
- Bernstein, 2010, A prospective population-based study of triggers of symptomatic flares in IBD, Am J Gastroenterol, 1994
- Schoultz, 2013, Assessment of causal link between psychological factors and symptom exacerbation in inflammatory bowel disease: A protocol for systematic review of prospective cohort studies, Syst Rev, 8
- Filipovic, 2007, Depression and anxiety levels in therapy-naive patients with inflammatory bowel disease and cancer of the colon, World J Gastroenterol, 438
- Rosenkranz, 2007, Substance P at the nexus of mind and body in chronic inflammation and affective disorders, Psychol Bull, 1007
- Rook, 2008, The hygiene hypothesis and psychiatric disorders, Trends Immunol, 150
- Graff, 2010, It′s not just about the gut: Managing depression and anxiety in inflammatory bowel disease, Pract Gastroenterol, 11
- Clarke, 2009, Can antidepressants influence the course of inflammatory bowel disease.The current state of research?, Eur Gastroenterol Hepatol Rev, 48
- Mikocka-Walus, 2012, A magic pill.A qualitative analysis of patients′ views on the role of antidepressant therapy in inflammatory bowel disease (IBD)?, BMC Gastroenterol, 93
- Janke, 2005, Determinants of life satisfaction in inflammatory bowel disease, Inflamm Bowel Dis, 272
- Yates, 2004, Clinical features of depressed outpatients with and without co-occurring general medical conditions in STARFNx01D, Gen Hosp Psychiatry, 421
- Mikocka-Walus, 2007, "It doesn′t do any harm, but patients feel better": A qualitative exploratory study on gastroenterologists′ perspectives on the role of antidepressants in inflammatory bowel disease, BMC Gastroenterol, 38
- Hansen, 2005, Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder, Ann Intern Med, 415
- Kubera, 2000, The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice, Psychoneuroendocrinology, 785
- Menon, 2011, A global perspective on gastrointestinal diseases, Gastroenterol Clin North Am, 427
- Bjelland, 2002, The validity of the Hospital Anxiety and Depression Scale.An updated literature review, J Psychosom Res, 69
- Lichtiger, 1994, Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med, 1841
- Development, 1998, The WHOQOL Group, Psychol Med, 551
- Diamond, 2006, Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade, Eur Neuropsychopharmacol, 481
- Iyengar, 2004, Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats, J Pharmacol Exp Ther, 576
- Lipkovich, 2014, Typology of patients with fibromyalgia: Cluster analysis of duloxetine study patients, BMC Musculoskelet Disord, 450
- Spiller, 2009, Overlap between irritable bowel syndrome and inflammatory bowel disease, Dig Dis, 48
- Bryant, 2011, Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status, J Gastroenterol Hepatol, 916
- Brennan, 2009, Duloxetine in the treatment of irritable bowel syndrome: An open-label pilot study, Hum Psychopharmacol, 423
- Mikocka-Walus, 2006, Antidepressants and inflammatory bowel disease: A systematic review, Clin Pract Epidemiol Ment Health, 24
- Rochelle, 2013, The importance of illness perceptions, quality of life and psychological status in patients with ulcerative colitis and Crohn′s disease, J Health Psychol, 972
Cited by
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment
Bisgaard, T. H., Allin, K. H., Keefer, L., Ananthakrishnan, A. N., & Jess, T. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00634-6 · Cited by 572
Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30089-5 · Cited by 354
Ge, L., Liu, S., Li, S., Yang, J., Hu, G., Xu, C., & Song, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016578 · Cited by 187
Opioid misuse in gastroenterology and non-opioid management of abdominal pain
Szigethy, E., Knisely, M., & Drossman, D. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.141 · Cited by 117
Antidepressants in inflammatory bowel disease
Mikocka-Walus, A., Ford, A. C., & Drossman, D. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0259-y · Cited by 93
Metadata
- Authors
- Sharbafchi, M., Daghaghzadeh, H., Naji, F., Afshar, H., Feizi, A., Maroufi, M., Tabatabaeeyan, M., Adibi, P., & Tavakoli, H.
- Venue
- Journal of Research in Medical Sciences
- Publisher
- Medknow
- Published
- 2015
- Volume
- 20
- Issue
- 6
- Pages
- 595
- ISSN
- 1735-1995 (ISSN-L)
- OpenAlex
- W2269262916
- Cited by
- 56
- References
- 15
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study. https://app.cochat.ai/papers/10.4103/1735-1995.165969
- The paper
- Sharbafchi, M., Daghaghzadeh, H., Naji, F., Afshar, H., Feizi, A., Maroufi, M., Tabatabaeeyan, M., Adibi, P., & Tavakoli, H. (2015). Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study. Journal of Research in Medical Sciences. https://doi.org/10.4103/1735-1995.165969
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.